EASO is pleased to join a new European initiative launched to improve the prevention, diagnosis and long-term management of cardiometabolic diseases, including obesity, diabetes, hypertension and cardiovascular disease.
IMPACT-MED is a five-year, €22.9 million project supported by the Innovative Health Initiative Joint Undertaking. The consortium, who convened in Rome during May 2026 for the project kick off meeting, brings together 26 partners across 13 countries, representing healthcare, research, industry and patient organisations.
Developing a more integrated model of care
Cardiometabolic diseases are closely interconnected and frequently occur together. However, they are often managed separately across different medical specialties, contributing to delayed diagnosis, fragmented treatment and limited support for long-term monitoring and self-management.
IMPACT-MED aims to address these gaps by developing and validating an integrated, multidisciplinary and person-centred model of cardiometabolic care.
The project will support the full continuum of care, from prevention and early detection through to treatment, remote monitoring, long-term follow-up and supported self-management. It aims to:
- Integrate different medical specialties within coordinated care pathways
- Improve early detection and personalised care through advanced diagnostics, predictive analytics and integrated health data
- Support people living with cardiometabolic diseases and healthcare professionals through remote monitoring, digital education and decision-support tools
- Improve continuity of care by reducing fragmentation and supporting more sustainable healthcare models
A connected digital ecosystem will bring together remote monitoring, wearable technologies, advanced imaging, biomarkers, patient-reported outcomes and interoperable digital platforms. These tools will help healthcare teams better understand individual needs, identify risks earlier and provide more proactive and personalised care.
Recognising obesity as a chronic disease
IMPACT-MED will promote an approach that reflects the reality of people living with multiple, interconnected chronic diseases. Integrating obesity within wider cardiometabolic pathways could support earlier diagnosis, more personalised treatment and improved access to coordinated, long-term care.
The project will test its approach through four clinical studies across five European sites. These will focus on AI-supported hypertension management, remote monitoring for chronic coronary syndrome, support for type 1 diabetes self-management, and personalised care for people living with type 2 diabetes and obesity.
IMPACT-MED is coordinated by Università Campus Bio-Medico di Roma, with Medtronic Ibérica as industrial leader.
For more information, visit:
- The project website: https://impactmed-ihi.eu/
- IMPACT-MED social media channels, LinkedIn et Ciel bleu
This project is supported by the Innovative Health Initiative Joint Undertaking under grant agreement No. 101253530. The IHI JU receives funding from the European Union’s Horizon Europe research and innovation programme and the industry associations COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe.
English 
French